Clal Insurance Enterprises Holdings Ltd Sells 100,000 Shares of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH)

Clal Insurance Enterprises Holdings Ltd decreased its holdings in shares of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) by 11.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 800,000 shares of the company’s stock after selling 100,000 shares during the period. Clal Insurance Enterprises Holdings Ltd owned approximately 16.49% of SPDR S&P Pharmaceuticals ETF worth $35,488,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in XPH. AlphaMark Advisors LLC lifted its position in SPDR S&P Pharmaceuticals ETF by 5.9% during the third quarter. AlphaMark Advisors LLC now owns 6,225 shares of the company’s stock valued at $276,000 after purchasing an additional 348 shares during the last quarter. Commonwealth Equity Services LLC increased its position in shares of SPDR S&P Pharmaceuticals ETF by 8.9% during the 2nd quarter. Commonwealth Equity Services LLC now owns 7,364 shares of the company’s stock valued at $293,000 after purchasing an additional 602 shares during the last quarter. Angeles Wealth Management LLC purchased a new position in shares of SPDR S&P Pharmaceuticals ETF during the 2nd quarter valued at about $40,000. Envestnet Portfolio Solutions Inc. lifted its position in SPDR S&P Pharmaceuticals ETF by 2.6% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 58,533 shares of the company’s stock worth $2,328,000 after buying an additional 1,510 shares during the last quarter. Finally, First Citizens Bank & Trust Co. boosted its stake in SPDR S&P Pharmaceuticals ETF by 2.7% in the second quarter. First Citizens Bank & Trust Co. now owns 65,826 shares of the company’s stock worth $2,619,000 after buying an additional 1,709 shares in the last quarter.

SPDR S&P Pharmaceuticals ETF Stock Performance

XPH stock opened at $46.57 on Friday. SPDR S&P Pharmaceuticals ETF has a one year low of $36.49 and a one year high of $48.76. The company has a market capitalization of $225.86 million, a PE ratio of 14.39 and a beta of 0.87. The company’s 50 day moving average price is $45.53 and its two-hundred day moving average price is $42.98.

SPDR S&P Pharmaceuticals ETF Profile

SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.